1. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
- Author
-
Grazia Fazio, Michela Bardini, Margherita Vieri, Giuseppe Gaipa, Garry P. Nolan, Shai Izraeli, Gianluca Fossati, Kara L. Davis, Cristina Bugarin, Giovanni Cazzaniga, Angela Maria Savino, Chiara Palmi, LH Meyer, Livio Trentin, Jolanda Sarno, G te Kronnie, Andrea Biondi, Savino, A, Sarno, J, Trentin, L, Vieri, M, Fazio, G, Bardini, M, Bugarin, C, Fossati, G, Davis, K, Gaipa, G, Izraeli, S, Meyer, L, Nolan, G, Biondi, A, Te Kronnie, G, Palmi, C, and Cazzaniga, G
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Adolescent ,medicine.drug_class ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Cell Line, Tumor ,Nitriles ,STAT5 Transcription Factor ,Animals ,Humans ,Medicine ,Phosphorylation ,Receptors, Cytokine ,Givinostat ,STAT5 ,biology ,business.industry ,Histone deacetylase inhibitor ,JAK-STAT signaling pathway ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Xenograft Model Antitumor Assays ,BCP-ALL, CRLF2 ,Histone Deacetylase Inhibitors ,Haematopoiesis ,Leukemia ,Pyrimidines ,030104 developmental biology ,Oncology ,chemistry ,Child, Preschool ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,biology.protein ,Pyrazoles ,Female ,Carbamates ,Stem cell ,business - Abstract
Leukemias bearing CRLF2 and JAK2 gene alterations are characterized by aberrant JAK/STAT signaling and poor prognosis. The HDAC inhibitor givinostat/ITF2357 has been shown to exert anti-neoplastic activity against both systemic juvenile idiopathic arthritis and myeloproliferative neoplasms through inhibition of the JAK/STAT pathway. These findings led us to hypothesize that givinostat might also act against CRLF2-rearranged BCP-ALL, which lack effective therapies. Here, we found that givinostat inhibited proliferation and induced apoptosis of BCP-ALL CRLF2-rearranged cell lines, positive for exon 16 JAK2 mutations. Likewise, givinostat killed primary cells, but not their normal hematopoietic counterparts, from patients carrying CRLF2 rearrangements. At low doses, givinostat downregulated the expression of genes belonging to the JAK/STAT pathway and inhibited STAT5 phosphorylation. In vivo, givinostat significantly reduced engraftment of human blasts in patient-derived xenograft models of CRLF2-positive BCP-ALL. Importantly, givinostat killed ruxolitinib-resistant cells and potentiated the effect of current chemotherapy. Thus, givinostat in combination with conventional chemotherapy may represent an effective therapeutic option for these difficult-to-treat subsets of ALL. Lastly, the selective killing of cancer cells by givinostat may allow the design of reduced intensity regimens in CRLF2-rearranged Down syndrome-associated BCP-ALL patients with an overall benefit in terms of both toxicity and related complications.
- Published
- 2017
- Full Text
- View/download PDF